Interferon beta-1a (subcutaneous 44 µg 3 times weekly)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Interferon beta-1a (subcutaneous 44 µg 3 times weekly), covering 2017-12-14 to 2017-12-14. Get the full timeline:
Most recent: Clinical Trial Update: A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly [Phase 2]